Anrukinzumab
| Anrukinzumab | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Anrukinzumab is a monoclonal antibody that was developed for the treatment of asthma. It is a humanized antibody that targets the interleukin-13 (IL-13) cytokine, which plays a key role in the inflammatory process associated with asthma.
Mechanism of Action[edit]
Anrukinzumab works by binding to IL-13, a cytokine involved in the immune system's response to allergens. IL-13 is known to contribute to the pathophysiology of asthma by promoting inflammation, mucus production, and airway hyperresponsiveness. By inhibiting IL-13, anrukinzumab reduces these effects, potentially alleviating symptoms in patients with asthma.
Development and Clinical Trials[edit]
Anrukinzumab was initially developed by MedImmune, a subsidiary of AstraZeneca. The drug underwent several clinical trials to evaluate its safety and efficacy in treating asthma. However, the development of anrukinzumab was eventually discontinued.
During its clinical evaluation, anrukinzumab was administered to patients with moderate to severe asthma to assess its impact on lung function and asthma control. The trials aimed to determine the optimal dosing regimen and to identify any potential side effects associated with the treatment.
Potential Applications[edit]
While anrukinzumab was primarily investigated for asthma, the mechanism of targeting IL-13 suggests potential applications in other allergic and inflammatory diseases. IL-13 is implicated in conditions such as atopic dermatitis and chronic rhinosinusitis with nasal polyps, making it a target of interest for various therapeutic interventions.
Discontinuation[edit]
Despite the promising mechanism of action, the development of anrukinzumab was halted. The reasons for discontinuation could include insufficient efficacy in clinical trials, safety concerns, or strategic business decisions by the developing company.
Related pages[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
